Loading...
Keywords
Last Name
Institution

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intravenous Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Treatment of Children Hospitalized with RSV Illness


Collapse Biography 

Collapse Overview 
Collapse sponsor award id
MI-CP141

Collapse Time 
Collapse start date
2007-01-01
Collapse end date
2010-12-31